Home > Insider Trading > Filing (0000950170-24-120198)

Filing Details

Accession Number:: 0000950170-24-120198
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-11-01 18:18:43
Reporting Period:: 2024-10-30

Accepted Time:: 2024-11-01 18:18:43
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1863127	Tyra Biosciences Inc.	TYRA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1381980	S Nina Kjellson	C/O Tyra Biosciences, Inc. 2656 State Street Carlsbad CA 92008		No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2024-10-30	9,889	$16.17	3,926,706	No	4	S	Indirect	By Canaan XI L.P.
Common Stock	Disposition	2024-10-30	1,189	$16.17	472,207	No	4	S	Indirect	By 2020+ Co-Investment L.P. - Series 7
Common Stock	Disposition	2024-10-31	89,390	$16.46	3,837,316	No	4	S	Indirect	By Canaan XI L.P.
Common Stock	Disposition	2024-10-31	10,750	$16.46	461,457	No	4	S	Indirect	By 2020+ Co-Investment L.P. - Series 7
Common Stock	Disposition	2024-11-01	23,938	$16.54	3,813,378	No	4	S	Indirect	By Canaan XI L.P.
Commmon Stock	Disposition	2024-11-01	604	$17.16	3,812,774	No	4	S	Indirect	By Canaan XI L.P.
Common Stock	Disposition	2024-11-01	2,878	$16.54	458,579	No	4	S	Indirect	By 2020+ Co-Investment L.P. - Series 7
Common Stock	Disposition	2024-11-01	73	$17.16	458,506	No	4	S	Indirect	By 2020+ Co-Investment L.P. - Series 7

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Canaan XI L.P.
No	4	S	Indirect	By 2020+ Co-Investment L.P. - Series 7
No	4	S	Indirect	By Canaan XI L.P.
No	4	S	Indirect	By 2020+ Co-Investment L.P. - Series 7
No	4	S	Indirect	By Canaan XI L.P.
No	4	S	Indirect	By Canaan XI L.P.
No	4	S	Indirect	By 2020+ Co-Investment L.P. - Series 7
No	4	S	Indirect	By 2020+ Co-Investment L.P. - Series 7

Footnotes

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.66. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any.
The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.10 to $17.08. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.13 to $17.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.